key: cord-0874534-02s7oylb
authors: Koyama, Alain K.; Koumans, Emilia H.; Sircar, Kanta; Lavery, Amy; Hsu, Joy; Ryerson, A. Blythe; Siegel, David A.
title: Severe Outcomes, Readmission, and Length of Stay Among COVID-19 Patients with Intellectual and Developmental Disabilities
date: 2022-01-22
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.01.038
sha: 52d381052369d6e45482d6176fbec9349f6c2487
doc_id: 874534
cord_uid: 02s7oylb

OBJECTIVES: The aim of this study was to evaluate the association between intellectual and developmental disabilities (IDDs) and severe COVID-19 outcomes, 30-day readmission, and/or increased length of stay (LOS) using a large electronic administrative database. METHODS: Patients hospitalized with COVID-19 were identified between March 2020 and June 2021 from more than 900 hospitals in the United States. IDDs included intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD), and other intellectual disabilities. Outcomes included intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, mortality, and LOS. RESULTS: Among 643,765 patients with COVID-19, multivariate models showed that patients with any IDD were at a significantly greater risk of at least 1 severe outcome, 30-day readmission, or longer LOS than patients without any IDD. Compared with those without any IDD, patients with Down syndrome had the greatest odds of ICU admission (odds ratio [OR] and 95% confidence interval [CI]: 1.96 [1.73-2.21]), IMV (OR: 2.37 [2.07-2.70]), and mortality (OR: 2.33 [2.00-2.73]). Patients with ASD and those with Down syndrome both had over a 40% longer mean LOS. Patients with intellectual disabilities had a 23% (12-35%) increased odds of 30-day readmission. CONCLUSIONS: Results suggest that patients hospitalized with COVID-19 with IDD have a significantly increased risk of severe outcomes, 30-day readmission, and longer LOS.

To evaluate the association between intellectual and developmental disabilities (IDD) and severe COVID-19 outcomes, 30-day readmission and/or increased length of stay (LOS) using a large electronic administrative database.

Hospitalized COVID-19 patients were identified between March 2020 and June 2021 from over 900 hospitals in the United States. IDD included intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD), and other intellectual disabilities. Outcomes included intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, mortality, and LOS.

Among 643,765 COVID-19 patients, compared to patients without any IDD, multivariate models showed patients with any IDD were at significantly greater risk of at least one severe outcome, 30-day readmission, or longer LOS. Patients with Down syndrome compared to those without any IDD had the greatest odds of ICU admission (odds ratio [OR] 

Results suggest hospitalized COVID-19 patients with IDD have significant increased risk of severe outcomes, 30-day readmission, and longer LOS.

Keywords: developmental disorder, intellectual disability, autism, cerebral palsy, Down syndrome,

Intellectual and developmental disabilities (IDD) are a broad group of conditions which result in impairments in physical, learning, language, and/or behavior beginning during the developmental period. Comorbidities, immune dysfunction, or difficulty in accessing healthcare, may put individuals with IDD at greater risk of severe COVID-19 outcomes (Kamalakannan et al., 2021) . Population-based studies have predominately evaluated mortality risk but not other outcomes including length of stay (LOS) and readmission (Clift et al., 2021 , Karpur et al., 2021 , Perera et al., 2020 , Turk et al., 2020 . We evaluated whether IDD are associated with intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, all-cause in-hospital mortality and/or increased length of stay (LOS) using a large electronic administrative database.

Data were from the Premier Healthcare Database Special COVID-19 Release (Premier Applied Sciences, 2020), which includes discharge data from >900 hospitals representing approximately 20% of annual admissions in the United States (U.S.). COVID-19 patients discharged March 1, 2020 to June 30, 2021 were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) discharge codes of U07.1 (from April 2020) or B97.29 (March 2020 through April 2020). Presence of ≥1 ICD-10-CM code (codes in Table 1 ) for intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD) and other intellectual disabilities from January 2019 through the index hospitalization was used to ascertain IDD (categories were not mutually exclusive).

Mixed effects models accounted for clustering by hospitals. Model 1 adjusted for potential confounders including demographics (age, sex, race/ethnicity), socioeconomic factors (insurance type, urbanicity, U.S. Census Division), and also admission month to account for temporal variations in outcomes. As adjusting for individual comorbidities may lead to collinearity, Model 2 further adjusted for the Elixhauser comorbidity index, a commonly used measure of overall comorbidity burden comprising 29 conditions, which outperforms other comorbidity indices in predicting mortality (Moore et al., 2017 , Sharabiani et al., 2012 . Whereas Models 1 and 2 compared individuals with each IDD to individuals without the IDD (e.g. ASD vs. no ASD), Model 3 excluded patients with any IDD in the reference group (e.g. ASD vs. no IDD of any type), while controlling for the same covariates in Model 2. SAS 9.4 was used for statistical analyses.

Among 643,765 COVID-19 patients identified, patients with IDD were generally younger and more likely to be male than patients without an IDD (Table 1) . Table 2 shows adjusted estimates among patients with each IDD compared to patients without IDD. In all models, patients with intellectual disability had a 15-29% significantly higher mean odds of IMV, readmission, and mortality. Patients with Down syndrome were at the greatest risk of most outcomes, including approximately a two-fold significant increased mean odds of ICU admission, IMV, and mortality. Patients with ASD had a 21-40% significantly increased odds of ICU admission and IMV. In Model 1, individuals with other intellectual disabilities had a 44-61% increased odds of ICU admission, IMV, and readmission, though odds ratios were attenuated slightly in Models 2 and 3. All groups were at significantly higher risk of longer LOS; in all models, patients with Down syndrome or ASD had approximately 40% longer mean LOS.

Among hospitalized COVID-19 patients, results suggest an increased risk of severe COVID-19 outcomes, readmission, and longer LOS among patients with IDD, compared to those without IDD. Furthermore, the sample size allowed sufficient disaggregation of IDD to reveal qualitative differences in risk across conditions and outcomes. For example, although patients with Down syndrome had the highest risk of each outcome for severe COVID-19, there was no increased risk of readmission, possibly due to survival bias as mortality risk was high. A prior study in England also showed high mortality risk for patients with Down syndrome (Clift et al., 2021) . Increased readmission risk and longer LOS among patients with IDD may be attributed to immune dysfunction, behavioral challenges, and/or greater comorbidities (Akbari et al., 2021 , Kamalakannan et al., 2021 , Karpur et al., 2021 .

Strengths of the study include the large sample from geographically diverse hospitals. Limitations include: residual confounding, potential under-ascertainment of events (readmissions were only captured if they occurred in the same hospital as the index admission), and use of ICD-10-CM codes to identify IDD. Results may not be generalizable to hospitals not reflected in this database. For example, while some evidence suggests triaging practices may decrease access to interventions for patients with IDD and COVID-19 (Cieza et al., 2021) , the current study reported an increased risk of IMV, which may be due to differing practices and resource availability among included hospitals.

This study's findings add evidence to consider individuals with IDD as a high-risk population to prioritize for vaccines and emerging therapies. Additional studies may confirm these findings and identify mechanisms that may be driving risk .

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Characteristics, risk factors, and outcomes associated with readmission in COVID-19 patients: A systematic review and meta-analysis

Disability and COVID-19: ensuring no one is left behind

COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults

Higher values suggest a greater degree of comorbidity associated with mortality. Expressed as mean ± standard deviation

Down syndrome (Q90), autism spectrum disorder (F84) and other intellectual disabilities (F80 [Specific developmental disorders of speech and language

Results are from logistic models for dichotomous outcomes, and Poisson models for length of stay. Level of statistical significance (α=0.05) was adjusted for multiple comparisons using the Bonferroni-Holm method. Abbreviations: ICU = intensive care unit, IDD = intellectual and developmental disabilities, IMV = invasive mechanical ventilation Bolded estimates indicate statistical significance after Bonferroni-Holm adjustment Model 1: Age, sex, race/ethnicity, insurance type, admission month, urbanicity, and U.S. Census Division Model 2: Model 1 covariates, and Elixhauser comorbidity index Model 3: Same covariates as Model 2, but reference group excludes patients with any IDD Categories for intellectual and developmental disabilities are described in detail in the footnote for Table 1